Impact Biomedical Inc. is a majority owned subsidiary of DSS, Inc. The company has technology assets for licensing and partnering, products for distribution and sales, and strategic investments in healthcare.
Impact Biomedical Inc. provides unique technology provider and business capabilities in addressing unmet needs in human healthcare and wellness.
Technologies / Products
Summary: Impact Biomedical FDA / MedTech Pipeline U.S.
|Asset||Preclinical||Ph I||Ph II||Ph III||Approved||IP||Description|
|LineBacker||2029/2036||Small molecule x-bonded polyphenol compounds with potential application in neurological and inflammatory disorders.|
Summary : Impact Biomedical OTC/Consumer U.S.